Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

EMANATE: Eine Studie zu Setmelanotid bei Patienten mit spezifischen Genvarianten im MC4R-Signalweg

19. Oktober 2026 aktualisiert von: Rhythm Pharmaceuticals, Inc.

Eine randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie: Mehrere unabhängige Teilstudien zu Setmelanotid bei Patienten mit POMC/PCSK1-, LEPR-, NCOA1(SRC1)- oder SH2B1-Genvarianten im Melanocortin-4-Rezeptorweg

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

  • Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a)
  • Leptin receptor (LEPR; Sub-study 035b)
  • Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 [SCR1]; Sub-study 035c)
  • Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

296

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Berlin, Deutschland, 10117
        • Charite - Universitatsmedizin Berlin
      • Frankfurt, Deutschland, 60596
        • Endokrinologikum Frankfurt
      • Leipzig, Deutschland, 04103
        • Universitaetsklinikum Leipzig
      • Ulm, Deutschland, 89075
        • Universitaetsklinikum Ulm
      • Lyon, Frankreich, 69677
        • GH Est Hopital Femme Mere Enfant
      • Paris, Frankreich, 75651
        • Hu Pitie Salpetriere Aphp
      • Paris, Frankreich, 75771
        • Hopital Armand Trousseau
      • Pessac, Frankreich, 33604
        • Centre Hospitalier Universitaire (CHU) de Bordeaux
      • Saint-Denis, Frankreich, 97400
        • Hôpital Félix Guyon Bellepierre
      • Toulouse, Frankreich
        • CHU de Toulouse Hopital des Enfants
      • Rio, Griechenland, 26504
        • University of Patras School of Medicine
      • Petah Tikva, Israel, 49372
        • Hasharon Hospital
      • Ramat Gan, Israel, 52621
        • Chaim Sheba MC, Safra Children's Hospital
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2E1
        • University of Alberta - Alberta Diabetes Institute (ADI)
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • The Hospital for Sick Children
      • Rotterdam, Niederlande, 3015 GD
        • Erasmus Medisch Centrum
      • San Juan, Puerto Rico, 00925-253
        • University of Puerto Rico
      • San Juan, Puerto Rico, 00927
        • Puerto Rico Consortium for Clinical Investigation, Inc.
      • Barcelona, Spanien, 08950
        • Hospital Sant Joan de Deu, Barcelona
      • Cadiz, Spanien
        • Puerta del Mar University Hospital
      • Madrid, Spanien, 28040
        • Hospital Fundación Jimenez Díaz
      • Málaga, Spanien, 29010
        • Hospital Universitario Virgen de la Victoria de Málaga
      • Valencia, Spanien, 46014
        • Hospital General de Valencia
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85016
        • Phoenix Children's Hospital
      • Scottsdale, Arizona, Vereinigte Staaten, 85258
        • HonorHealth Bariatric Center
    • California
      • Los Angeles, California, Vereinigte Staaten, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, Vereinigte Staaten, 06519
        • Yale Center for Clinical Investigation
    • Florida
      • Altamonte Springs, Florida, Vereinigte Staaten, 32701
        • Advent Health
      • Gainesville, Florida, Vereinigte Staaten, 32610
        • University of Florida
    • Georgia
      • Suwanee, Georgia, Vereinigte Staaten, 30024
        • InQuest Medical Research
    • Massachusetts
      • Worcester, Massachusetts, Vereinigte Staaten, 01655
        • UMASS Memorial Medical Center
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48105
        • University of Michigan
      • Dearborn, Michigan, Vereinigte Staaten, 48126-2619
        • Metro Detroit Endocrinology Center
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55902
        • Mayo Clinic
    • Mississippi
      • Madison, Mississippi, Vereinigte Staaten, 39110
        • Mississippi Center for Advanced Medicine
    • Missouri
      • Chesterfield, Missouri, Vereinigte Staaten, 63017
        • St. Luke's Hospital
      • Kansas City, Missouri, Vereinigte Staaten, 64108
        • Children's Mercy
      • St Louis, Missouri, Vereinigte Staaten, 63130
        • Washington University in St. Louis
    • New York
      • Buffalo, New York, Vereinigte Staaten, 14260
        • University of Buffalo
      • New York, New York, Vereinigte Staaten, 10032
        • Columbia University
      • New York, New York, Vereinigte Staaten, 10029
        • Mount Sinai Hospital
      • New York, New York, Vereinigte Staaten, 10029
        • Metropolitan Hospital Center
      • Staten Island, New York, Vereinigte Staaten, 10306
        • Ten's Medical Center - Pediatric Endocrinology Clinic
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Danville, Pennsylvania, Vereinigte Staaten, 17822
        • Geisinger Clinic
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
        • UPMC Montefiore
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37232
        • Vanderbilt University School of Medicine
    • Texas
      • Amarillo, Texas, Vereinigte Staaten, 79106
        • Texas Tech
      • Houston, Texas, Vereinigte Staaten, 77030
        • Texas Children's Hospital
      • Houston, Texas, Vereinigte Staaten, 77084
        • Biopharma Informatic
      • McAllen, Texas, Vereinigte Staaten, 78503
        • Rio Grande Valley Endocrine Center
      • Plano, Texas, Vereinigte Staaten, 75093
        • Endocrine Associates of Dallas and Plano
    • Washington
      • Tacoma, Washington, Vereinigte Staaten, 98405
        • MultiCare Health System Institute for Research and Innovation
    • West Virginia
      • Morgantown, West Virginia, Vereinigte Staaten, 26506
        • West Virginia University
    • Wisconsin
      • Marshfield, Wisconsin, Vereinigte Staaten, 54449
        • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc
      • Bristol, Vereinigtes Königreich, BS2 8AE
        • Bristol Royal Hospital for Children
      • Cambridge, Vereinigtes Königreich, CB2 0QQ
        • University of Cambridge
      • Liverpool, Vereinigtes Königreich, L9 7AL
        • Aintree University Hospital
      • London, Vereinigtes Königreich, W2 1NY
        • Imperial College Healthcare Trust
      • London, Vereinigtes Königreich, NW1 2PG
        • London Medical - The London Diabetes Centre
      • London, Vereinigtes Königreich, WC1E6JF
        • University College London Hospitals NHS Foundation Trust
      • Manchester, Vereinigtes Königreich, M13 9WL
        • Manchester Children's Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

6 Jahre bis 65 Jahre (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Participants must have a pre-identified:

    • Heterozygous genetic variant in the POMC gene or PCSK1 gene
    • Heterozygous genetic variant in the LEPR gene
    • Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
    • Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
  • Between 6 and 65 years of age at the time of provision of informed consent/assent

  • Obesity, defined as body mass index (BMI) ≥30 kg/m^2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 up to 17 years of age

  • Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent

  • Participant and/or parent or guardian reports that participant experienced childhood obesity, defined as the participant and/or parent or guardian reporting that the participant had obesity or was significantly overweight during childhood

  • Agree to use a highly effective form of contraception throughout the study and for 90 days following the study

  • Reported history of lifestyle intervention of diet and exercise

  • Symptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.

Key Exclusion Criteria:

  • Weight loss of 2% or greater in the previous 3 months
  • Bariatric surgery or procedure within the previous 6 months
  • Significant psychiatric disorder(s)
  • Suicidal ideation, attempt or behavior
  • Clinically significant pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
  • Glycated hemoglobin (HbA1C) >10% at Screening
  • History of significant liver disease or severe kidney disease
  • History or close family history (parents or siblings) of melanoma, or participant history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant hypersensitivity to any excipient in the study drug
  • If female, pregnant or breastfeeding

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: POMC or PCSK1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimental: LEPR variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimental: NCOA1 (SRC1) variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimental: SH2B1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
Zeitfenster: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters [m])^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.

Baseline, Week 52

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
Zeitfenster: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
Zeitfenster: Baseline, Week 52

Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration

Baseline, Week 52
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
Zeitfenster: Baseline, Week 52

Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
Zeitfenster: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
Zeitfenster: Baseline, Week 52

BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
Zeitfenster: Baseline, Week 52

The percentage change from baseline in BMI 95th percentile was calculated as ([BMI at Week 52 / BMI 95th percentile]) - [BMI at baseline / BMI 95th percentile])*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Waist Circumference
Zeitfenster: Baseline, Week 52

The waist circumference (in centimeters [cm]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Zeitfenster: Baseline up to 60 weeks

TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Baseline up to 60 weeks
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
Zeitfenster: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
Zeitfenster: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
Zeitfenster: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
Zeitfenster: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
Zeitfenster: Baseline, Week 52

Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienstuhl: David Meeker, MD, Rhythm Pharmaceuticals, Inc.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

26. April 2022

Primärer Abschluss (Tatsächlich)

19. Dezember 2025

Studienabschluss (Tatsächlich)

30. Juni 2026

Studienanmeldedaten

Zuerst eingereicht

30. September 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Oktober 2021

Zuerst gepostet (Tatsächlich)

26. Oktober 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • RM-493-035

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .